Topic: sickle cell disease
GBT, a pioneer in the sickle cell field with recently approved Oxbryta, sees an example to emulate as it embarks on its first launch: HIV.
Novartis and GBT won long-awaited approvals for sickle cell treatments, but ICER says the drugs are far too expensive based on their clinical benefit.
With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.
Global Blood Therapeutics has its first drug approval, and it’s one that’ll bring a “paradigm shift” in how patients with SCD are treated, execs say.